A Canadian R&D Leader
GlaxoSmithKline Inc. (GSK) is one of the largest research and development (R&D) organizations in Canada. GSK invested more than $110 million in Canadian research and development (R&D) in 2014, ranking it among the top 30 contributors to R&D in Canada, across all industries.
- In 2012, GSK invested $40 million in conducting 58 clinical trials across Canada, and involving over 3,500 patients.
- In 2012, GSK supported more than 40 Investigator Sponsored Studies with physicians across Canada.
- In 2012, GSK sponsored approximately 23 local trials (health economics and outcomes research, phase IV) to support the scientific understanding of our medicines and vaccines in Canada.
Supporting R&D Innovation in Canada
To accelerate the discovery of new medicines and vaccines, we make collaboration part of our business model. Partnering with academic researchers and public organisations is a key part of our research efforts and we have a range of projects in place to allow us to work with and support new projects that fall within the specific areas of science we are interested in exploring.
In Canada, GSK is actively engaged in the support of research and innovation in the life sciences, and the commercialization of new technologies. GSK works actively with academic researchers, university industry liaison and technology transfer offices, and innovation hubs such as MaRS Innovation, the Centre for Drug Research and Development (CDRD), and the Quebec Consortium for Drug Development (CQDM), to identify exciting new opportunities in drug discovery and development for potential collaboration with GSK.
Find out about the main areas of science we are focusing on, how we conduct our research, what drives our R&D operations, and view our product pipeline.
Sharing our research
As part of our commitment to transparency, we are reporting the results of all our research, where the outcomes are perceived to be positive or negative. You can read more about this commitment here.